List of Defitelio drug patents
Defitelio is owned by Jazz Pharms Inc.
Defitelio contains Defibrotide Sodium.
Defitelio has a total of 2 drug patents out of which 0 drug patents have expired.
Defitelio was authorised for market use on 30 March, 2016.
Defitelio is available in solution;intravenous dosage forms.
Defitelio can be used as treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct).
The generics of Defitelio are possible to be released after 22 June, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11236328 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(9 years from now) | |
| US11085043 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 30, 2023 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
Market Authorisation Date: 30 March, 2016
Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct)
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic